WALTHAM, Mass.– Trinity Life Sciences, a leader in global life sciences solutions, is sharing findings from its latest TGaS Landscape report entitled, “Market Access Trends and Consideration for 2021: A Biopharma Perspective.” The report, based on in-depth interviews with Market Access leaders from pre-commercial and commercial biopharma companies, finds that the top two challenges for market access teams in 2021 are pricing pressures and evidence generation.
“Pricing pressures continue to increase for treatments that have limited competition as well as those that are in more competitive environments,” said Rebecca Villari, VP, Market Access and Reimbursement. “Generating evidence that supports the value story is a strategic imperative for market access teams.”
The findings reflect much of the demand that Trinity has seen from clients in the past year.
“Our research continues to show that demand for value demonstration from payers is only increasing. In response, Trinity has continually expanded its capabilities to match this need,” said Eric Matckie, President of Value & Access at Trinity. “In addition to our strategic pricing, market access, reimbursement, and contracting practice (SPARC), we have made significant investments in our Health Economics and Outcomes Research (HEOR) and evidence generation Center of Excellence to support the value narrative.”
